Lucatumumab (CHIR 12.12 or HCD122)[1] is a human monoclonal antibody against CD40[2] development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.

[3] It is an antagonist to CD40 that was created by scientists at Chiron using Abgenix' XenoMouse transgenic mouse to generate fully human antibodies.

[4][5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.

[11] Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.